Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 29, 2013. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 718,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,680.50 pence per share; lowest price paid was 1,663.50 pence per share.
- Treasury Holdings (Settled): 514,119,412 shares (9.50% of total issued share capital).
- Treasury Holdings (Including Unsettled): 516,272,412 shares (10.54% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,899,407,123 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 718,000 shares on August 29, 2013. Consequently, the percentage of total voting rights held in Treasury increased to 10.54% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,899,407,123) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.54% including unsettled shares).
- Review the price paid per share (1,663.50 to 1,680.50 pence) against market prices on August 29, 2013.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.